Colorectal Cancer Clinical Trial
Official title:
Effectiveness of a Brief Telephone Intervention to Improve Participation in a Colorectal Cancer Screening Program: a Randomized Controlled Trial
| Verified date | January 2019 |
| Source | Corporacion Parc Tauli |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Objective: To assess the effectiveness of a brief telephone intervention added to an post
invitation letter in the participation rate to a colorectal cancer screening program.
Methods: Randomized controlled trial. This study is framed inside the colorectal cancer
screening program of Catalonia, concretely in the region of Vallès Occidental. This program
is directed to men and women from 50 to 69 years. The screening test used is the fecal
immunological test (FIT) that is offered every 2 years. If the screening test is positive, a
colonoscopy with sedation is offered as a diagnostic test.
| Status | Completed |
| Enrollment | 432 |
| Est. completion date | December 20, 2017 |
| Est. primary completion date | July 31, 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 49 Years to 70 Years |
| Eligibility |
Inclusion Criteria: - Women and men from 50 to 69 years living in the selected territories (Terrassa C, Terrassa A, Cerdanyola del Vallès 1) that will be invited for the first time in the Colorectal cancer screening program. Exclusion Criteria: - The same as those used in the population program: 1. History of colorectal cancer; 2. History of inflammatory bowel disease; 3. history of colorectal adenomas; 4. family history of polyposis syndromes or hereditary nonpolyposis colorectal cancer; 5. family history of colorectal cancer if: two first grade relatives affected or only one fist grade relative affected diagnosed before the age of 60; 6. terminal illness or severe disability which contraindicates the study of the colon. People is excluded temporally if: - 1) they have a colonoscopy performed in the last 5 years; - 2) present digestive signs or symptoms (rectal bleeding, change in bowel habits, abdominal pain, weight loss with fatigue and anorexia, abdominal mass); - 3) they express the will to be out of the Program. |
| Country | Name | City | State |
|---|---|---|---|
| Spain | Corporació Sanitària Parc Taulí | Sabadell | Barcelona |
| Lead Sponsor | Collaborator |
|---|---|
| Corporacion Parc Tauli |
Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Participation | Participation is defined as the number of people who do the screening test to the total of people invited to the Program. | 6 months | |
| Secondary | Knowledge of the program | proportion of people from the intervention group who report knowing the existence of the program. | 1 day at the time of intervention administration | |
| Secondary | Comprehension of the information received | proportion of people from the intervention group who report having understood in which the screening program consists of. | 1 day at the time of intervention administration | |
| Secondary | Help to decide about participation | proportion of people from the intervention group who report that the information received in the phone call will be useful to decide about their participation in the program. | 1 day at the time of intervention administration |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |